Ginkgo Bioworks Quarterly Balance Sheet
NYSE: DNAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ginkgo Bioworks financial position
As of Jun 30, 2026, Ginkgo Bioworks reported total assets of $990.0 million, down 19.6% from a year earlier against total liabilities of $569.8 million. Shareholders' equity stood at $420.3 million, or 42.5% of assets. The company held $84.5 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 4.57, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Ginkgo Bioworks balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 84.53M | 143.86M | 167.20M | 111.06M | 203.57M | 312.42M | 561.57M | 616.21M | 730.37M | 840.44M | 944.07M | 1.05B |
| Short-Term Investments | — | — | 255.42M | 384.42M | 355.79M | 12.84M | 0 | — | — | — | — | — |
| Receivables | 13.01M | 19.82M | 24.03M | 21.43M | 22.15M | 26.29M | 21.86M | 23.41M | 18.59M | 24.19M | 17.16M | 61.90M |
| Inventory | — | — | — | — | — | — | — | — | — | — | 46.00K | 70.00K |
| Total Current Assets | 332.54M | 409.95M | 471.84M | 506.08M | 523.02M | 564.53M | 602.74M | 662.48M | 783.36M | 903.02M | 1.00B | 1.14B |
| Property, Plant & Equipment | 157.19M | 163.02M | 167.37M | 176.58M | 186.35M | 197.83M | 203.72M | 211.03M | 210.58M | 195.99M | 188.19M | 201.59M |
| Goodwill | — | — | — | — | — | — | 0 | 0 | 0 | 47.91M | 49.24M | 58.06M |
| Intangible Assets | 44.39M | 48.86M | 53.48M | 61.52M | 66.15M | 68.76M | 72.51M | 79.57M | 90.60M | 77.41M | 82.74M | 100.17M |
| Total Assets | 990.05M | 1.03B | 1.12B | 1.19B | 1.23B | 1.29B | 1.38B | 1.48B | 1.63B | 1.58B | 1.67B | 2.03B |
| Accounts Payable | 9.57M | 16.31M | 10.57M | 10.70M | 11.20M | 11.27M | 14.17M | 15.70M | 23.03M | 27.00M | 9.32M | 10.75M |
| Total Current Liabilities | 72.74M | 79.59M | 95.97M | 115.28M | 96.72M | 115.67M | 107.27M | 114.43M | 166.15M | 169.04M | 163.86M | 168.46M |
| Total Liabilities | 569.76M | 589.92M | 611.11M | 629.38M | 618.06M | 646.04M | 661.39M | 682.94M | 792.18M | 594.49M | 568.19M | 773.71M |
| Shareholders' Equity | 420.28M | 443.15M | 508.59M | 559.78M | 612.95M | 647.43M | 716.06M | 797.94M | 833.07M | 987.27M | 1.10B | 1.25B |
| Retained Earnings | -6.28B | -6.23B | -6.15B | -6.07B | -5.99B | -5.93B | -5.84B | -5.73B | -5.67B | -5.46B | -5.29B | -5.08B |
| Net Cash (Debt) | 84.53M | 143.86M | 422.62M | 495.48M | 559.36M | 325.26M | 561.57M | 616.21M | 730.37M | 840.44M | 944.07M | 1.05B |
| Shares Outstanding | 63.71M | 61.66M | 58.21M | 56.84M | 55.43M | 54.70M | 54.37M | 53.08M | 2.08B | 2.03B | 50.03M | 1.97B |
This table shows 12 quarterly periods of Ginkgo Bioworks's balance sheet, from Q2 2026 back to Q3 2023, across 16 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow DNA's reporting calendar. What is a balance sheet?